- Conditions
- Plaque Psoriasis
- Interventions
- PH-10 (rose bengal disodium 0.001%), Control
- Drug
- Lead sponsor
- Provectus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Psoriasis
- Interventions
- Topical Rose Bengal, 0.005%
- Drug
- Lead sponsor
- Provectus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Miami, Florida • Chapel Hill, North Carolina • Austin, Texas
- Conditions
- Melanoma
- Interventions
- PV-10, Surgery
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Atopic Dermatitis
- Interventions
- PH-10
- Drug
- Lead sponsor
- Provectus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Miami, Florida • New York, New York
- Conditions
- Cutaneous Melanoma
- Interventions
- PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
- Drug
- Lead sponsor
- Provectus Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 12
- States / cities
- San Diego, California • Miami Beach, Florida • Tampa, Florida + 9 more
- Conditions
- Melanoma
- Interventions
- PV-10 (10% rose bengal disodium)
- Drug
- Lead sponsor
- Provectus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- San Francisco, California • Louisville, Kentucky • Bethlehem, Pennsylvania + 1 more
- Conditions
- Psoriasis
- Interventions
- PH-10 (0.001% Rose Bengal)
- Drug
- Lead sponsor
- Provectus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Miami, Florida • New York, New York
- Conditions
- Melanoma
- Interventions
- PV-10, Pembrolizumab
- Drug
- Lead sponsor
- Provectus Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Lebanon, New Hampshire • Portland, Oregon + 2 more
- Conditions
- Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory, Approved Alternative Therapy
- Interventions
- PV-10 (10% rose bengal disodium)
- Drug
- Lead sponsor
- Provectus Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Bethlehem, Pennsylvania • Houston, Texas
- Conditions
- Psoriasis
- Interventions
- PH-10 (0.002% Rose Bengal), PH-10 (0.005% Rose Bengal), PH-10 (0.01% Rose Bengal), Vehicle
- Drug
- Lead sponsor
- Provectus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Oceanside, California • Miami, Florida • New York, New York + 1 more
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer
- Interventions
- PV-10 (10% rose bengal disodium)
- Drug
- Lead sponsor
- Provectus Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 5
- States / cities
- San Diego, California • Tampa, Florida • Bethlehem, Pennsylvania + 2 more